Lawmakers: FDA holds key to orphan drug development
By Mari Serebrov
Thursday, March 6, 2014
Whenever the number of drug approvals drops, especially for rare diseases, the FDA points a finger at drugmakers, saying its approvals are limited by the applications it receives.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.